Derivation of Human Toxicokinetic Parameters and Chemical-Specific Adjustment Factor of Citrinin Through a Human Intervention Trial and Hierarchical Bayesian Population Modeling
Visintin et al.
The finding, in our words
Researchers validated a UHPLC-MS/MS assay for citrinin in capillary blood collected with Neoteryx Mitra VAMS devices, plus feces and urine, achieving quantification limits of 0.05 ng/mL. The study derived human toxicokinetic parameters from 48-hour sample collection after a single oral dose, demonstrating that microsampling enables robust population-level exposure assessment for mycotoxins.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study validated a method for measuring the alcohol biomarker phosphatidylethanol using two volumetric absorptive microsampling devices, finding that the Mitra device met all validation criteria and agreed with venous sampling. The Capitainer device was deemed suitable but showed reduced accuracy at higher concentrations, with a small proportional negative bias compared to venous results.
Andreassen et al., Journal of analytical toxicology (paywalled) · source ↗
The authors found that a single microdose of recombinant EPO was detectable up to 72 hours using ITP and CP methods, though the Tasso microsampling device showed lower sensitivity than Mitra and Capitainer. Additionally, isotope ratio mass spectrometry successfully detected testosterone micro-dosing in all analysed samples, supported by serum testosterone levels.
Heiland et al., Drug testing and analysis · source ↗
Capillary VAMS combined with direct mercury analysis demonstrated strong correlation with venous blood mercury concentrations in adult volunteers, with acceptable accuracy and precision above 1.0 µg/l. Storage in pre-cleaned glass vials following two hours of desiccator drying maintained analyte stability for at least four weeks.
Koutsimpani-Wagner et al., Environmental monitoring and assessment · source ↗
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
A post-mortem case study found that Mitra microsampling devices achieved comparable qualitative toxicological detection to conventional methods across blood, urine, bile, and vitreous humour, successfully identifying methamphetamine, opioids, and alpha-PHP. Whilst limited to a single case, this shows that microsampling is a viable alternative for qualitative screening when sample volumes are restricted.
Magny et al., Forensic science international (paywalled) · source ↗